Preferred Label : NVX-CoV2373 adjuvated lipid nanoparticle;
CISMeF synonym : recombinant SARS-CoV-2 vaccine NVX-cov2373; rSARS-cov-2 vaccine;
MeSH synonym : NVX-cov2373; NVX-CoV2373 COVID-19 vaccine;
MeSH hyponym : Novavax COVID-19 vaccine;
UNII : 2SCD8Q63PF;
Origin ID : C000711928;
UMLS CUI : C5416844;
Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
PUBLIÉ LE 25/01/2023
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-22-12-2022-au-19-01-2023
2023
false
false
false
France
French
mRNA Vaccine
mRNA Vaccines
NVX-CoV2373 adjuvated lipid nanoparticle
summary of product characteristics
package leaflet
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
mRNA vaccine
Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines
---
PUBLIÉ LE 17/05/2023
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-13-04-2023-au-11-05-2023
2023
false
false
false
France
French
mRNA Vaccine
mRNA Vaccines
NVX-CoV2373 adjuvated lipid nanoparticle
summary of product characteristics
package leaflet
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines
---
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-16-03-2023-au-13-04-2023
2023
false
false
false
France
French
mRNA Vaccine
mRNA Vaccines
NVX-CoV2373 adjuvated lipid nanoparticle
summary of product characteristics
package leaflet
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines
---
PUBLIÉ LE 31/03/2023
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-10-02-2023-au-16-03-2023
2023
false
false
false
France
French
mRNA Vaccine
mRNA Vaccines
NVX-CoV2373 adjuvated lipid nanoparticle
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines
---
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-14-04-2023-au-8-06-2023
2023
false
false
false
France
French
mRNA Vaccine
mRNA Vaccines
NVX-CoV2373 adjuvated lipid nanoparticle
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines
---
PUBLIÉ LE 27/02/2023
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-13-01-2023-au-16-02-2023
2023
false
false
false
France
French
mRNA Vaccine
mRNA Vaccines
NVX-CoV2373 adjuvated lipid nanoparticle
summary of product characteristics
package leaflet
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
mRNA vaccine
Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines
---
PUBLIÉ LE 27/12/2022
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-25-11-2022-au-22-12-2022
2022
false
false
false
France
French
mRNA Vaccine
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
NVX-CoV2373 adjuvated lipid nanoparticle
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
mRNA vaccine
Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid
2022
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
COVID-19 Vaccines
vaccination
COVID-19
covid-19, protein subunit
adult
adjuvants, immunologic
Vaccine Efficacy
Immunogenicity, Vaccine
NVX-CoV2373 adjuvated lipid nanoparticle
NVX-CoV2373 adjuvated lipid nanoparticle
recombinant proteins
spike protein, SARS-CoV-2
injections, intramuscular
pregnancy
breast feeding
product surveillance, postmarketing
drug evaluation, preclinical
drug storage
---
https://www.inspq.qc.ca/publications/3206-utilisation-vaccin-covid-19-novavax
2022
false
false
false
Canada
COVID-19
COVID-19 Vaccines
public health guidelines
Vaccinia
vaccine, nos
NVX-CoV2373 adjuvated lipid nanoparticle
vaccination
vaccines
Vaccins
vaccinia
vaccination
preventive immunization/medication
---
https://www.has-sante.fr/jcms/p_3309579/fr/strategie-de-vaccination-contre-la-covid-19-place-du-vaccin-nuvaxovid-nvx-cov2373
2022
false
false
false
France
COVID-19
vaccination
drug approval
NVX-CoV2373 adjuvated lipid nanoparticle
france
vaccine strategy
vaccine prioritization
recombinant protein subunit vaccine
vaccines, recombinant
adult
first vaccination
injections, intramuscular
Immunogenicity, Vaccine
vaccine potency
vaccine adverse event
SARS-CoV-2 variants
covid-19, protein subunit
public health guidelines
COVID-19 Vaccines
vaccination
---
